Jun-Feng Wang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2372995/publications.pdf

Version: 2024-02-01

46 papers

3,860 citations

218381 26 h-index 42 g-index

46 all docs

46 docs citations

times ranked

46

4846 citing authors

#	Article	IF	CITATIONS
1	Increased hippocampal bdnf immunoreactivity in subjects treated with antidepressant medication. Biological Psychiatry, 2001, 50, 260-265.	0.7	1,028
2	Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders. International Journal of Neuropsychopharmacology, 2011, 14, 123-130.	1.0	462
3	Mitochondrial Complex I Activity and Oxidative Damage to Mitochondrial Proteins in the Prefrontal Cortex of Patients With Bipolar Disorder. Archives of General Psychiatry, 2010, 67, 360.	13.8	382
4	Increased oxidative stress in the anterior cingulate cortex of subjects with bipolar disorder and schizophrenia. Bipolar Disorders, 2009, $11,523-529$.	1.1	217
5	Chronic Treatment with Mood Stabilizers Lithium and Valproate Prevents Excitotoxicity by Inhibiting Oxidative Stress in Rat Cerebral Cortical Cells. Biological Psychiatry, 2005, 58, 879-884.	0.7	185
6	Oxidative damage to RNA but not DNA in the hippocampus of patients with major mental illness. Journal of Psychiatry and Neuroscience, 2010, 35, 296-302.	1.4	132
7	G Protein-Coupled Cyclic AMP Signaling in Postmortem Brain of Subjects with Mood Disorders. Journal of Neurochemistry, 2001, 73, 1121-1126.	2.1	122
8	Unpredictable chronic mild stress not chronic restraint stress induces depressive behaviours in mice. NeuroReport, 2014, 25, 1151-1155.	0.6	100
9	Gene expression differences in bipolar disorder revealed by cDNA array analysis of post-mortem frontal cortex. Journal of Neurochemistry, 2008, 79, 826-834.	2.1	87
10	Prefrontal cortex glutathione S-transferase levels in patients with bipolar disorder, major depression and schizophrenia. International Journal of Neuropsychopharmacology, 2011, 14, 1069-1074.	1.0	84
11	Mood stabilizing drug lithium increases expression of endoplasmic reticulum stress proteins in primary cultured rat cerebral cortical cells. Life Sciences, 2006, 78, 1317-1323.	2.0	81
12	Regulation of ER stress proteins by valproate: therapeutic implications. Bipolar Disorders, 2002, 4, 145-151.	1.1	69
13	Chronic unpredictable stress impairs endogenous antioxidant defense in rat brain. Neuroscience Letters, 2015, 584, 208-213.	1.0	69
14	Glutathione Sâ€transferase is a novel target for mood stabilizing drugs in primary cultured neurons. Journal of Neurochemistry, 2004, 88, 1477-1484.	2.1	65
15	Increased expression of endoplasmic reticulum stress proteins following chronic valproate treatment of rat C6 glioma cells. Neuropharmacology, 2000, 39, 2162-2169.	2.0	61
16	The role of neuroinflammation and amyloid in cognitive impairment in an <scp>APP</scp> / <scp>PS</scp> 1 transgenic mouse model of Alzheimer's disease. CNS Neuroscience and Therapeutics, 2017, 23, 310-320.	1.9	59
17	Identification of Lithium-Regulated Genes in Cultured Lymphoblasts of Lithium Responsive Subjects with Bipolar Disorder. Neuropsychopharmacology, 2004, 29, 799-804.	2.8	56
18	Regulation of GAP-43 expression by chronic desipramine treatment in rat cultured hippocampal cells. Biological Psychiatry, 2003, 53, 530-537.	0.7	50

#	Article	IF	Citations
19	Amygdala cyclic adenosine monophosphate response element binding protein phosphorylation in patients with mood disorders: effects of diagnosis, suicide, and drug treatment. Biological Psychiatry, 2004, 55, 570-577.	0.7	50
20	Defects of Mitochondrial Electron Transport Chain in Bipolar Disorder: Implications for Mood-Stabilizing Treatment. Canadian Journal of Psychiatry, 2007, 52, 753-762.	0.9	42
21	Chronic restraint stress decreases the expression of glutathione S-transferase pi2 in the mouse hippocampus. Brain Research, 2006, 1090, 156-162.	1.1	34
22	Immunoreactivity of 43kDa growth-associated protein is decreased in post mortem hippocampus of bipolar disorder and schizophrenia. Neuroscience Letters, 2007, 411, 123-127.	1.0	34
23	Decreased expression of insulin-like growth factor binding protein 2 in the prefrontal cortex of subjects with bipolar disorder and its regulation by lithium treatment. Brain Research, 2007, 1147, 213-217.	1.1	32
24	Mood stabilizer lithium inhibits amphetamine-increased 4-hydroxynonenal-protein adducts in rat frontal cortex. International Journal of Neuropsychopharmacology, 2012, 15, 1275-1285.	1.0	30
25	Lamotrigine Increases Gene Expression of GABA-A Receptor Î ² 3 Subunit in Primary Cultured Rat Hippocampus Cells. Neuropsychopharmacology, 2002, 26, 415-421.	2.8	29
26	Upregulation of Thioredoxin-Interacting Protein in Brain of Amyloid- \hat{l}^2 Protein Precursor/Presenilin 1 Transgenic Mice and Amyloid- \hat{l}^2 Treated Neuronal Cells. Journal of Alzheimer's Disease, 2019, 72, 139-150.	1.2	28
27	Platelet Protein Kinase C alpha Levels in Drug-Free and Lithium-Treated Subjects with Bipolar Disorder. Neuropsychobiology, 1999, 40, 63-66.	0.9	27
28	Txnip mediates glucocorticoid-activated NLRP3 inflammatory signaling in mouse microglia. Neurochemistry International, 2019, 131, 104564.	1.9	26
29	Identification of mood stabilizer-regulated genes by differential-display PCR. International Journal of Neuropsychopharmacology, 2001, 4, 65-74.	1.0	25
30	Wilson's disease: Update on integrated Chinese and Western medicine. Chinese Journal of Integrative Medicine, 2013, 19, 233-240.	0.7	23
31	Quetiapine Attenuates Glial Activation and Proinflammatory Cytokines in APP/PS1 Transgenic Mice via Inhibition of Nuclear Factor-ÂB Pathway. International Journal of Neuropsychopharmacology, 2015, 18, pyu022-pyu022.	1.0	21
32	Identification of a novel lithium regulated gene in rat brain. Molecular Brain Research, 1999, 70, 66-73.	2.5	20
33	Mood stabilizing drugs lamotrigine and olanzapine increase expression and activity of glutathione s-transferase in primary cultured rat cerebral cortical cells. Neuroscience Letters, 2009, 455, 70-73.	1.0	19
34	Abstinence from repeated amphetamine treatment induces depressive-like behaviors and oxidative damage in rat brain. Psychopharmacology, 2013, 227, 605-614.	1.5	19
35	Regulatory role of cathepsin L in induction of nuclear laminopathy in Alzheimer's disease. Aging Cell, 2022, 21, e13531.	3.0	17
36	Increased thioredoxin-interacting protein in brain of mice exposed to chronic stress. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 88, 320-326.	2.5	15

#	Article	lF	CITATIONS
37	Upregulation ofÂantioxidant thioredoxin by antidepressants fluoxetine andÂvenlafaxine. Psychopharmacology, 2020, 237, 127-136.	1.5	15
38	Chronic treatment with mood stabilizer lithium inhibits amphetamine-induced risk-taking manic-like behaviors. Neuroscience Letters, 2015, 603, 84-88.	1.0	13
39	Glucocorticoid Upregulates Thioredoxin-interacting Protein in Cultured Neuronal Cells. Neuroscience, 2018, 384, 375-383.	1.1	12
40	Insulin-like growth factor binding protein-2 expression is decreased by lithium. NeuroReport, 2006, 17, 897-901.	0.6	10
41	Regulation of molecular chaperone GRP78 by mood stabilizing drugs. Clinical Neuroscience Research, 2004, 4, 281-288.	0.8	7
42	Nitric oxide donor SIN-1 mediated down-regulation of the G-protein \hat{l}_{\pm} -subunit in C6 glioma cells. Life Sciences, 1997, 60, 1279-1285.	2.0	2
43	Understanding the neurobiology of bipolar depression. , 2009, , 77-94.		1
44	G Proteins and Mood Disorders. , 1997, , 353-378.		0
45	Oxidative protein modification of soluble Nâ€ethylmaleimideâ€sensitive factor attachment protein receptors. FASEB Journal, 2013, 27, .	0.2	0
46	Mitochondrial Dysfunction and Oxidative Stress in Bipolar Disorder., 2014,, 2411-2429.		0